Medicenna Therapeutics (TSE:MDNA) Trading Down 6.3%
Shares of Medicenna Therapeutics Corp (TSE:MDNA) were down 6.3% during trading on Thursday . The company traded as low as C$1.18 and last traded at C$1.18, approximately 6,700 shares were traded during trading. A decline of 81% from the average daily volume of 36,165 shares. The stock had previously closed at C$1.26.
The firm has a market cap of $38.01 million and a P/E ratio of -6.45. The firm has a fifty day moving average of C$1.38.
About Medicenna Therapeutics (TSE:MDNA)
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.
Featured Article: Using other technical indicators with support levels
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.